0001001277-12-000077.txt : 20121228 0001001277-12-000077.hdr.sgml : 20121228 20121228132616 ACCESSION NUMBER: 0001001277-12-000077 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20121224 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20121228 DATE AS OF CHANGE: 20121228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China Botanic Pharmaceutical CENTRAL INDEX KEY: 0000926844 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841273503 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34808 FILM NUMBER: 121290036 BUSINESS ADDRESS: STREET 1: LEVEL 11, CHANGJIANG INTL BLDG STREET 2: NO.28, CHANGJIANG ROAD,NANGANG DISTRICT, CITY: HARBIN, HEILONGJIANG PROVINCE STATE: F4 ZIP: 150090 BUSINESS PHONE: 86-451-5762-0378 MAIL ADDRESS: STREET 1: LEVEL 11, CHANGJIANG INTL BLDG STREET 2: NO.28, CHANGJIANG ROAD,NANGANG DISTRICT, CITY: HARBIN, HEILONGJIANG PROVINCE STATE: F4 ZIP: 150090 FORMER COMPANY: FORMER CONFORMED NAME: RENHUANG PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060816 FORMER COMPANY: FORMER CONFORMED NAME: ANZA CAPITAL INC DATE OF NAME CHANGE: 20020521 FORMER COMPANY: FORMER CONFORMED NAME: E-NET FINANCIAL COM CORP DATE OF NAME CHANGE: 20000317 8-K 1 form8-k.htm form8-k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): (December 24, 2012)


China Botanic Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)


Nevada
(State or Other Jurisdiction of
Incorporation)
  
001-34808
(Commission File Number)
  
88-1273503
(IRS Employer
Identification No.)

     
 
Level 11, Changjiang International Building
No. 28, Changjiang Road
Nangang District, Harbin
Heilongjiang Province, P.R. China
 (Address of Principal Executive Offices)
  
 
 
 
 
150090
(Zip Code)


+86-451-5762-0378
(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
1
 

Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a)           On December 24, 2012, Mr. Zack Pan notified China Botanic Pharmaceutical Inc.  (the “Company”) that he was resigning as the Chair of the Audit Committee, member of the Compensation Committee and the Nominations Committee, and as a director of the Company, effective December 24, 2012. In his written correspondence to the Company, a copy of which is attached as an exhibit to this Form 8-K, Mr. Pan stated that his decision to resign was due to his personal reasons.

 
Item 9.01                      Financial Statements and Exhibits.
 
 
(d)           Exhibits.
 
 
Exhibit No.                                Description
 
17.1
Letter of Resignation, dated December 24, 2012, of Zack Pan addressed to Chairman Li Shaoming and the Board of Directors

 
SIGNATURE
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
China Botanic Pharmaceutical Inc.
a Nevada Corporation


Dated: December 27, 2012                                            /s/ Li Shaoming                                                                                              
Li Shaoming,
Chief Executive Officer


 
 
 
 
2
 

 

 



 EX-17 2 ex17-1.htm ex17-1.htm
 
EXHIBIT 17.1
 
 

 
 
Dear Chairman Mr. Li Shaoming and CBP Board,
 
 
Due to the fact that the Company failed to renew the D&O insurance policy, the liability risks of public companies make it impossible for me to continue to serve on the Board and as the audit committee chairman of China Botanic Pharmaceuticals, Inc.(CBP). I hereby resign  the position  as the independent director and audit committee chairman of CBP, effective immediately as of today December 24, 2012 (U.S. time). The Company is required to file an 8K advising SEC  the change (departure) of its director within four business days . Please consult with the Company legal counsel about the 8K filing with SEC and also the notification of NYSE.
 
 
Sincerely,
 
Zack Pan